Lpath, Inc.’s iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients |  |
|
Posted by BioSpace.com Featured News October 7th, 2009 .
| |
| No Comments |
SAN DIEGO, CA--(Marketwire - October 08, 2009) - Lpath, Inc. (OTCBB: LPTN), the categoryleader in lipidomics-based therapeutics, reported positive summary resultsof its single-dose Phase 1 clinical trial of iSONEP™ in wet-AMDpatients.
iSONEP met its primary endpoint of being well tolerated...
See other entries categorized in BioSpace, News, Syndication.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
